Elton John Aids Foundation (EJAF)

The Elton John Aids Foundation is one of the top 10 philanthropic funders of hiv/aids grants worldwide. Since our founding, we have raised over $600 million to support hiv/aids programs globally. We are in the top 5 funders of hiv/aids programming for marginalized communities such as gay men, transgender, sex workers and people who use drugs, supporting groups that face a disproportionate burden of the hiv/aids pandemic and taking on issues that governments are often unable or unwilling to fund. In 2023, our u.s. and u.k. Entities together funded $21,647,822 of new grants, the highest amount ever awarded in one year. The u.s. Entity alone awarded $16,422,921 of grants and spent $19,646,690 on program services, 89% of total expenses. See schedule o for continuation.in 2020, we embarked on an exciting new strategic plan, designed to reduce stigma and hiv transmission, ensure that everyone has access to compassionate care and treatment, and that governments invest equitably in those populations most affected by hiv. Our strategy focuses on reaching the most marginalized populations and communities that are so often left behind and excluded from the hiv response.the Elton John Aids Foundation's grantmaking is made from both its u.s. Entity (to which this form 990 relates) and u.k. Entity. As reported in the Foundation's annual report, available on our website, the Foundation awarded 56 new grants to the value of $21,647,822 in 2023, of which $16,422,921 was from the u.s. Entity alone. We reached over 280,000 people with services and education across 42 countries, initiated over 8,900 people on pre-exposure prophylaxis (prep), initiated over 11,000 on antiretroviral therapy (art) and supported over 113,000 people to test for hiv. Grants were awarded across our strategic portfolio areas:1. Young people: to meet the growing global health needs of young people and prevent a resurgence of the hiv/aids pandemic, we will pilot and scale effective public health responses which meet young people where they are through innovations in sexual and reproductive health and mental health service delivery. 2. Lgbtq+: lgbtq+ populations are at increased risk of hiv infection due to pervasive inequalities and injustices, which can no longer be ignored. We are working to ensure lgbtq+ people have equal rights and protection under the law, social power, and access appropriate, quality health care.3. United states of america: the hiv/aids epidemic in the united states will not end without concerted action from both the public and private sector. We are strengthening these partnerships to enhance health workforce capabilities, to increase the accessibility and demand for hiv prevention and testing commodities, to enhance linkages to care within communities, and to address national, state, and local policy barriers for people living with hiv and those at heightened risk of infection.4. Eastern europe and central asia: in eastern europe and central asia, hiv infections and aids-related deaths continue to rise, demanding urgent action to turn the tide of the epidemic. To achieve epidemic control in eeca, we are working to improve and expand hiv services for all, to reduce stigma and discrimination experienced by key populations, and to share learning on effective approaches. In response to the outbreak of war in ukraine and increased burdens on the health system, we are making strategic investments to bolster and sustain the hiv/aids response during this crisis. 5. People who use drugs: criminalization, violence, and a lack of political will continue to impede hiv/aids prevention and treatment outcomes for people who use drugs. We are working to ensure people who use drugs are free from criminalization, have access to relevant and effective harm reduction strategies, and can rely on continued political commitment and investment to meet their health needs.elton John Aids Foundation Inc. was founded by sir Elton John and is governed by a board of philanthropic leaders, technical experts, and leaders in the global hiv/aids response. Financial review:2023 was another strong year financially for the Elton John Aids Foundation as we continue to make good progress against our 2020-2025 strategy. The Foundation consists of a u.k entity and a u.s. subsidiary entity (to which this form 990 relates), in combination referred to as the "group". The directors manage the grant-making, fundraising, and other operations of the organisation jointly across the group. As reported in the annual report available on our website, total combined revenue for the group in 2023 was $32,905,087, an excellent result driven by the launch of the rocket fund, our $125 million, multi-year fundraising initiative to accelerate the Foundation's lifesaving work and combat the growing rates of hiv. In the u.s. Entity alone, $21,618,939 of total revenue was generated in 2023, the second highest amount achieved in its 30-year history, second only to the exceptional $29,188,898 in 2022. The decrease in revenue in the u.s. Entity compared to 2022 is largely due to the u.k. Entity receiving an increased proportion of the group's overall income, driven by management's decision to direct all funding from its key gilead partnership to the u.k. Entity in 2023. We are enormously proud of the programmatic success we've achieved in 2023 and the impact we've had on the lives of people in every corner of the world. As the result of our network of generous donors, supporters, and partners the Foundation was able to fund 102 innovative programs across four continents and approved 56 new grants to the value of $21,647,822 across the group, as reported in the annual report the highest amount ever awarded in one year. In the u.s. Entity alone, $16,422,921 of grants were awarded and total expenses on program services were $19,646,690, representing 89% of total expenses in the entity. The Foundation took the strategic decision to increase and maximise the value of grants to partners and expenditure on program services in 2023 using the surpluses generated in 2022 and the strong net assets held at the start of 2023. As reported in the annual report, the group ran a deficit of $8,409, offset by $581,592 of gains on investments, resulting in net assets of $33,787,385 at december 31, 2023 ($33,214,202 at december 31, 2022). As reported in this form 990, the u.s. Entity ran a deficit of $547,683, which was offset by $437,415 of unrealized gains on investments and other changes in net assets, resulting in net assets of $15,740,294 at december 31, 2023 ($15,850,562 at december 31, 2022). The strong net asset position held by both the group and the u.s. Entity going into 2024 means the Foundation can continue to prioritize funding the important work of our partners.